ABIN393600
antibody from antibodies-online
Targeting: NCOA6
AIB3, ASC2, KIAA0181, NRC, PRIP, RAP250, TRBP
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN393600 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Nuclear Receptor Coactivator 6 (NCOA6) (AA 1954-2064) antibody
- Antibody type
- Monoclonal
- Description
- This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 1954-2064
- Isotype
- IgG
- Antibody clone number
- 2D7
- Vial size
- 100 μg
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Submitted references Association of a common AGO1 variant with lung cancer risk: a two-stage case-control study.
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity.
PRIP promotes tumor formation through enhancing serum-responsive factor-mediated FOS expression.
Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.
Kim JS, Choi YY, Jin G, Kang HG, Choi JE, Jeon HS, Lee WK, Kim DS, Kim CH, Kim YJ, Son JW, Jung TH, Park JY
Molecular carcinogenesis 2010 Oct;49(10):913-21
Molecular carcinogenesis 2010 Oct;49(10):913-21
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR
Molecular medicine (Cambridge, Mass.) 2010 Jul-Aug;16(7-8):247-53
Molecular medicine (Cambridge, Mass.) 2010 Jul-Aug;16(7-8):247-53
ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity.
Kim DH, Lee J, Lee B, Lee JW
Molecular endocrinology (Baltimore, Md.) 2009 Oct;23(10):1556-62
Molecular endocrinology (Baltimore, Md.) 2009 Oct;23(10):1556-62
PRIP promotes tumor formation through enhancing serum-responsive factor-mediated FOS expression.
Zhu YT, Hu L, Qi C, Zhu YJ
The Journal of biological chemistry 2009 May 22;284(21):14485-92
The Journal of biological chemistry 2009 May 22;284(21):14485-92
Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.
Lu Y, Dollé ME, Imholz S, van 't Slot R, Verschuren WM, Wijmenga C, Feskens EJ, Boer JM
Journal of lipid research 2008 Dec;49(12):2582-9
Journal of lipid research 2008 Dec;49(12):2582-9
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB